AbbVie's Mavyret (glecaprevir and pibrentasvir) Receives FDA's Approval for All Genotypes of Hepatitis C in Pediatric Patients
Shots:
- The approval follows the clinical study results assessing Mavyret (glecaprevir & pibrentasvir) in 47 children aged 12-17 yrs. with genotype 1- 2- 3 or 4 HCV infection without/mild Cirrhosis resulted in no virus detection @12wks. after receiving Mavyret for 8/16wks.
- The study assessing Mavyret in pediatric patients with cirrhosis/history of a kidney or liver transplant/genotype 5 or 6 HCV infection- safety & efficacy follows the clinical study conducted in adults in 2017
- Mavyret is an oral combination therapy of glecaprevir (ABT-493- broad-genotypic NS3/4A protease inhibitor) and pibrentasvir (ABT-530- NS5A inhibitor) and has received FDA’s PR & BT designation for HCV in adults
Ref: The US FDA | Image:AbbVie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com